FDA
-
-
-
-
-
-
-
FDA grants priority review to Genentech's Gazyva for kidney disease
-
-
-
-
-
-
-
FDA grants priority review for Genentech's Tecentriq in stage III colon cancer
-
-
-
-
-
-
-
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
-
-
-
-
-
-
-
Roche gets FDA clearance for two new laboratory analytical units
-
-
-
-
-
-
-
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
-
-
-
-
-
-
-
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
-
-
-
-
-
-
-
FDA approves Genentech's Gazyva for lupus nephritis treatment
-
330,175 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

